BlackThorn begins Phase II dosing of BTRX-140 for depression
BTRX-140 is being developed to treat major depressive disorder, among other neurobehavioral disorders. Credit: ryan melaugh.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more